PMPRB Cancellation of March 18th Policy Forum
The Patented Medicines Prices Review Board (PMPRB) has announced the cancellation of its Policy Forum expected to be held on March 18th, 2020 amid the evolving COVID-19 situation.
In order to provide stakeholders with an opportunity to convey information that may ... Read More
10
Mar2020
26
Feb2020
PDCI is pleased to inform you of the launch of its podcast series, Between the Lines. Between the Lines invites thought leaders and industry experts to share their insights about the trends and controversies that are shaping the pharmaceutical policy ... Read More
25
Feb2020
Sharing Responses to the Patented Medicine Prices Review Board (PMPRB) Draft Guidelines Consultation
On November 21, 2019, the PMPRB published its draft Guidelines and launched a public consultation as a step towards implementing the recently amended Patented Medicines Regulations. Since then, the PMPRB has engaged with stakeholders to obtain feedback on its proposed pricing Guidelines. The consultation period closed on February 14, ... Read More
14
Feb2020
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website.
In this Pharmaceutical Reviews Update, CADTH made program updates ... Read More
13
Feb2020
Following the publication of the PMPRB Draft Guidelines on Nov 21, 2019, PDCI undertook an analysis to critically assess the impact of the PMPRB regulatory changes published in August 2019, as proposed to be implemented in the Draft Guidelines.
Top-Line Summary
The PMPRB regulatory changes and Draft ... Read More
29
Jan2020
PDCI is excited to announce the promotion of Andrea Lau to the position of Associate Director, HTA and Clinical Evaluation.
Andrea has been with PDCI for over 3 years, and in that time has been invaluable ... Read More
14
Jan2020
W. Neil Palmer
In its December 2019 NEWSletter[1], the Patented Medicine Prices Review Board (PMPRB) is “reminding” patentees that they are required under the Patent Act (the Act) and the Patented Medicines Regulations (the Regulations) to file all zero-dollar sales, referring specifically to free goods. This “reminder” is troubling ... Read More
26
Nov2019
REGISTRATION IS OPEN!
Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement
Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members ... Read More
21
Nov2019
Pricing changes for Canada’s patented medicines are on their way and stakeholders are anticipating the release of the updated guidelines. How will the guidelines be operationalized? How will the new pharmacoeconomic factors be implemented? In an effort to answer these questions, PDCI has attempted to reverse-engineer the proposed Pharmacoeconomic Value ... Read More